Literature DB >> 3049187

Clinical approach to the management of intractable epilepsy.

J Aicardi1.   

Abstract

Resistance of seizures to anti-epileptic therapy may be due to patient error, or to physician diagnostic and/or treatment error, rather than being truly intractable epilepsy. Increased drug dosage, irrespective of blood levels, a change of drug, or the addition of a second drug, are variously indicated in truly resistant cases. The use of more than two drugs is better avoided, and in some cases reduction of treatment may improve seizure control while lessening side-effects. Repeated assessment of patients with refractory epilepsy is important, as causative or provocative factors may remain latent for long periods. Surgical therapy probably should be used more often and earlier than it now is for epilepsies that are medically intractable.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049187     DOI: 10.1111/j.1469-8749.1988.tb04769.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  9 in total

Review 1.  Management of intractable epilepsy.

Authors:  J H Livingston
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

2.  Treatment of epilepsy in people with multiple handicap.

Authors:  H Foley
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

Review 3.  Corticosteroids in the management of the paediatric epilepsies.

Authors:  R Gupta; R Appleton
Journal:  Arch Dis Child       Date:  2005-04       Impact factor: 3.791

4.  Rapid anticonvulsant monitoring in an epilepsy clinic.

Authors:  P N Houtman; S K Hall; A Green; G W Rylance
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

5.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

6.  Optimum method for administration of biosynthetic human growth hormone: a randomised crossover trial of an Auto Injector and a pen injection system.

Authors:  R Stanhope; A Albanese; L Moyle; G Hamill
Journal:  Arch Dis Child       Date:  1992-08       Impact factor: 3.791

7.  High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study.

Authors:  B G van Engelen; W O Renier; C M Weemaes; P F Strengers; P J Bernsen; S L Notermans
Journal:  Eur J Pediatr       Date:  1994-10       Impact factor: 3.183

Review 8.  Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy.

Authors:  A Fitton; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

9.  Subchronic treatment with antiepileptic drugs modifies pentylenetetrazol-induced seizures in mice: Its correlation with benzodiazepine receptor binding.

Authors:  Luisa Rocha
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.